NAGE Q3 2025 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+32.9% YoY

Gross Profit

$22M64.5% margin

Operating Income

$4M12.5% margin

Net Income

$5M13.5% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$98M

Total Liabilities

$27M

Stockholders' Equity

$71M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$26M	+32.9%
Gross Profit	$22M	$16M	+35.0%
Operating Income	$4M	$2M	+164.4%
Net Income	$5M	$2M	+143.8%